Cover

pdf iconDownload PDF
 

Frontmatter

pdf iconDownload PDF
 

Contents

pdf iconDownload PDF

pp. vii-viii

read more

Acknowledgments

pdf iconDownload PDF

pp. ix-x

Beyond having a substantial impact on my clinical practice and thinking, researching and writing the history of medicine is simply fun (to echo Sherwin Nuland). Being able to thank those who have made this possible is perhaps even more fun. I have been...

read more

Introduction: Patterns of Resistance

pdf iconDownload PDF

pp. 1-8

In September of 1937—two years after the introduction of Prontosil and sulfanilamide, the first of the sulfa drugs—a close relative of John D. Rockefeller Jr. was admitted to the exclusive Phillips House of the Massachusetts General Hospital with pneumococcal pneumonia. The patient’s physicians called in experts...

read more

PART I: SEROTHERAPY AND THE RISE OF THE SPECIFIC, 1891 – 1930

pdf iconDownload PDF

pp. 9-11

“Pneumonia,” wrote two clinicians on the eve of antipneumococcal serotherapy in 1890, “is a representative disease.”1 From the standpoints of nosology (the classification of disease) and diagnosis, the tempo and mode of change regarding pneumonia as a disease entity over the past two...

read more

1 The Advent of Type-Specific Antipneumococcal Serotherapy

pdf iconDownload PDF

pp. 13-21

The first twenty-two years of antipneumococcal serotherapy’s evolution were hardly auspicious. By 1897, while the treatment of diphtheria through the neutralization of its toxin with antitoxin was being hailed as the crowning glory of laboratory science, the existence of a pneumococcal toxin itself was called into...

read more

2 A “Specific” Specific and the Turbid Age of Applied Immunology

pdf iconDownload PDF

pp. 22-34

In the first edition of his Principles and Practice of Medicine (1892), William Osler placed pneumonia, not within the section on specific infectious diseases, but under “diseases of the respiratory system.”1 Lamenting that “we have, then, no specific for pneumonia,” Osler perhaps nowhere else so firmly expressed a belief in...

read more

3 Fundamental Tensions: Clinical “Proof” and Clinical Resistance

pdf iconDownload PDF

pp. 35-50

The treatment of pneumonia—on account of the disease’s marked variability in severity from patient to patient and from year to year—had long provided a challenging yet alluring subject for those concerned with the methodology of “proving” therapeutic efficacy. Pierre Louis, for example, had in the 1830s used...

read more

PART II: THE TRANSFORMATION OF PNEUMONIA INTO A PUBLIC HEALTH CONCERN, 1930 – 1939

From Boston and New York, proponents of antipneumococcal serotherapy in the early 1930s would continue to answer their critics while at the same time introducing methodological innovations concerning serotherapy’s efficacy, range, and ease of administration that would continue to change...

read more

4 The Massachusetts Experiment and New (York) Tensions

pdf iconDownload PDF

pp. 53-67

Before describing in detail the advent of the Massachusetts and New York efforts to transform pneumonia into a public health concern, it is useful to place such efforts in the context of the rapidly changing nature of antipneumococcal serotherapy itself. As Lloyd Felton’s concentrated serum (either monovalent against...

read more

5 The New Standard, the New Deal, and the Pneumonia Control Programs

pdf iconDownload PDF

pp. 68-87

By the late 1930s, many of the tensions exposed and further engendered by antipneumococcal serotherapy over the previous two decades (as discussed in chapter 3) seemed to be resolving in the wake of contingent technological improvements on the one hand, and a continued therapeutic reorientation toward the use and...

read more

PART III: RESOLUTION: THE ANTIMICROBIAL "REVOLUTION" AND THE DECLINE OF SEROTHERAPY, 1939 – PRESENT

Few events in modern medicine have been considered as revolutionary as the advent of the sulfa drugs and antibiotics in the late 1930s and early 1940s. On the one side of the divide stood, amidst a wealth of academic knowledge, a groping collective impotence; on the other, the conquest of

read more

6 Histology of a Revolution

pdf iconDownload PDF

pp. 91-114

Histology, of course, depends as much on the mode of presentation of materials as it does on a magnified viewing of its subject. For ease of presentation, I have therefore divided this longest chapter into three chronologically ordered sub-groupings, highlighting: the resistance engendered by serum advocates against...

read more

7 A “Modern” Revolution: The Limits and Uses of Controlled Clinical Trials

pdf iconDownload PDF

pp. 115-131

The tempo of the antipneumococcal chemotherapeutic “revolution” reflected the competing impacts of a number of clinical and economic forces. Chapter 6 has already emphasized the degree to which the pragmatics of practice—the inertias, implementation infrastructures, and variously defined costs of the two respective...

read more

8 The Dismantling of Pneumonia as a Public Health Concern

pdf iconDownload PDF

pp. 132-146

The informational void that the pharmaceutical companies could fill with their rhetoric would be enlarged by the dismantling of pneumonia itself as a public health concern by the end of World War II. And as I relate in this chapter, many of the present dilemmas facing public health advocates with respect to...

read more

Conclusion: Overcoming Resistance

pdf iconDownload PDF

pp. 147-149

Throughout this book, I have attempted to use the evolving treatment of pneumonia as a lens through which to examine the changing “therapeutic perspective” of twentieth-century American medicine. Several key themes have emerged: the profession’s increasing focus on the use of the specific; the changing means...

Notes

pdf iconDownload PDF

pp. 151-246

Index

pdf iconDownload PDF

pp. 247-254